| 22.53 -0.33 (-1.44%) | 09-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 32.7 | 1-year : | 38.19 |
| Resists | First : | 28 | Second : | 32.7 |
| Pivot price | 21.93  |
|||
| Supports | First : | 20.67 | Second : | 16.14 |
| MAs | MA(5) : | 23.91 |
MA(20) : | 21.8 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0 | Signal : | 0 |
| %K %D | K(14,3) : | 48.3  |
D(3) : | 58 |
| RSI | RSI(14): 55.8 |
|||
| 52-week | High : | 28 | Low : | 16.14 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ATTO ] has closed below upper band by 30.5%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 26.26 - 26.4 | 26.4 - 26.52 |
| Low: | 22.02 - 22.18 | 22.18 - 22.31 |
| Close: | 22.62 - 22.86 | 22.86 - 23.07 |
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Wed, 09 Sep 2026
Attovia Therapeutics, Inc. (NASDAQ:ATTO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Mon, 07 Sep 2026
Attovia Therapeutics, Inc.'s (NASDAQ:ATTO) Quiet Period To End on September 14th - MarketBeat
Sat, 05 Sep 2026
Analysts Offer Insights on NA Companies: Attovia Therapeutics, Inc. (ATTO) and Navan, Inc. Class A (NAVN) - The Globe and Mail
Thu, 03 Sep 2026
Attovia Therapeutics to Participate in Upcoming Citi and Morgan Stanley Investor Conferences - Quiver Quantitative
Thu, 03 Sep 2026
Attovia Therapeutics to Participate in Upcoming Investor Conferences - finance.yahoo.com
Wed, 02 Sep 2026
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - finance.yahoo.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 2.508e+007 (%) |
| Held by Institutions | 8.8 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.525e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 845.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 1.8e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -67 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 511870 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|